The first patient has been dosed in the P-I (ABSK061-101) trial evaluating the safety, tolerability & PK of ABSK061 in patients with advanced solid tumors. The trial is currently being conducted in China & US
The trial will determine the RP2D & evaluate preliminary anti-tumor activities. The usage of ABSK061 in non-oncology indications incl. achondroplasia has a great potential to grow in addition to its oncology uses
ABSK061 is an orally available, highly potent & selective small-molecule FGFR2/3 inhibitor independently discovered & developed by Abbisko with global IP rights. Multiple other pan-FGFR inhibitors showed clinical efficacy in multiple types of tumor carrying FGFR2/3 alterations & have been approved globally, including China & US
Ref: PRNewswire| Image: Abbisko Therapeutics
